Fortress Biotech, Inc. (FBIO)
NASDAQ: FBIO · Real-Time Price · USD
2.760
+0.060 (2.22%)
At close: Oct 20, 2025, 4:00 PM EDT
2.700
-0.060 (-2.17%)
After-hours: Oct 20, 2025, 7:45 PM EDT
Fortress Biotech Revenue
Fortress Biotech had revenue of $16.41M in the quarter ending June 30, 2025, with 10.18% growth. This brings the company's revenue in the last twelve months to $59.30M, down -28.23% year-over-year. In the year 2024, Fortress Biotech had annual revenue of $57.68M, down -31.76%.
Revenue (ttm)
$59.30M
Revenue Growth
-28.23%
P/S Ratio
1.15
Revenue / Employee
$587,139
Employees
101
Market Cap
82.12M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 57.68M | -26.84M | -31.76% |
Dec 31, 2023 | 84.51M | 8.77M | 11.58% |
Dec 31, 2022 | 75.74M | 6.95M | 10.11% |
Dec 31, 2021 | 68.79M | 23.19M | 50.86% |
Dec 31, 2020 | 45.60M | 8.97M | 24.49% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
FBIO News
- 12 days ago - Journey Medical Corporation to Participate in October 2025 Investor Conferences - GlobeNewsWire
- 19 days ago - Fortress Biotech Investigated by the Portnoy Law Firm - GlobeNewsWire
- 19 days ago - Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing - GlobeNewsWire
- 19 days ago - Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101 - GlobeNewsWire
- 6 weeks ago - Journey Medical Corporation to Participate in September 2025 Investor Conferences - GlobeNewsWire
- 6 weeks ago - Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Journey Medical Corporation to Present at the Emerging Growth Conference - GlobeNewsWire
- 2 months ago - Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire